12:42 PM EST, 01/28/2025 (MT Newswires) -- Atai Life Sciences ( ATAI ) said Tuesday the results of a phase 2a study of Beckley Psytech's BPL-003 in patients with moderate to severe alcohol use disorder were encouraging.

The open-label study involved 12 patients, who were given a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy, the company said.

The combination resulted in "meaningful and sustained reduction in alcohol use and heavy drinking days" in the 12-week study, it said.

BPL-003 also demonstrated a favorable safety profile, with adverse events characterized as mild or moderate, Atai said.

Beckley Psytech is partly own by Atai.

Atai shares were down more than 3% in recent trading.

Price: 1.40, Change: -0.05, Percent Change: -3.45